Suppression of immune response by antigen-modified liposomes encapsulating model agents: A novel strategy for the treatment of allergy

Ichikawa, Kanae; Asai, Tomohiro; Shimizu, Kosuke; Yonezawa, Sei; Urakami, Takeo; Miyauchi, Haruna; Kawashima, Hiroto; Ishida, Tatsuhiro; Kojima, Hiroshi; Oku, Naoto

doi:10.1016/j.jconrel.2013.02.002

Cited by 20 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A remote‐loading method was used for encapsulation of DOX into the liposomes . In brief, the thin lipid film was hydrated with 0.3 M citric acid solution (pH 4.0).…”

Section: Methodsmentioning

confidence: 99%

Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment

et al. 2015

Self Cite

View full text Add to dashboard Cite

Bauhinia purprea agglutinin (BPA) is a well‐known lectin that recognizes galactosyl glycoproteins and glycolipids. In the present study, we firstly found that BPA bound to human prostate cancer specimens but not to normal prostate ones. Therefore, we sought to develop BPA‐PEG‐modified liposomes (BPA‐PEG‐LP) encapsulating anticancer drugs for the treatment of prostate cancer. We examined the tumor targetability of BPA‐PEG‐LP with human prostate cancer DU145 cells, and observed that fluorescently labeled BPA‐PEG‐LP dominantly associated with the cells via the interaction between liposome‐surface BPA and cell‐surface galactosyl molecules. We also observed that BPA‐PEG‐LP accumulated in the prostate cancer tissue after the i.v. injection to DU145 solid cancer‐bearing mice, and strongly bound to the cancer cells. In a therapeutic study, DU145 solid cancer‐bearing mice were i.v. injected thrice with BPA‐PEG‐LP encapsulating doxorubicin (BPA‐PEG‐LPDOX, 2 mg/kg/day as the DOX dosage) or PEG‐modified liposomes encapsulating DOX (PEG‐LPDOX). As a result, BPA‐PEG‐LPDOX significantly suppressed the growth of the DU145 cancer cells, whereas PEG‐LPDOX at the same dosage as DOX showed little anti‐cancer effect. The present study suggested that BPA‐PEG‐LP could be a useful drug carrier for the treatment of human prostate cancers.

show abstract

“…A remote‐loading method was used for encapsulation of DOX into the liposomes . In brief, the thin lipid film was hydrated with 0.3 M citric acid solution (pH 4.0).…”

Section: Methodsmentioning

confidence: 99%

Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…When presensitized mice were treated with these liposomes, OVA‐specific IgE was strongly suppressed whereas IgG1 levels were not affected, but also decreased using high‐density OVA liposomes. Additional loading of these liposomes with doxorubicin further reduced OVA‐specific IgE probably by eradication of OVA‐specific B cells in the spleen . Finally, multilamellar, small unilamellar, and reversed phase vesicle liposomes were analyzed regarding encapsulation efficiency of house dust mite allergens, but no cellular tests were performed …”

Section: Biodegradable Nanostructuresmentioning

confidence: 99%

Recent advances in the use of nanoparticles for allergen‐specific immunotherapy

Pohlit

Bellinghausen

Frey

et al. 2017

Allergy

View full text Add to dashboard Cite

The number of patients suffering from allergic asthma and rhinoconjunctivitis has increased dramatically within the last decades. Allergen‐specific immunotherapy (AIT) is the only available cause‐oriented therapy so far. AIT reduces symptoms, but has also a disease‐modifying effect. Disadvantages are a long‐lasting procedure, and in a few cases potential systemic adverse reactions. Encapsulation of allergens or DNA vaccines into nanostructures may provide advantages compared to the conventional AIT with noncapsulated allergen extracts: The protein/DNA molecule can be protected from degradation, higher local concentrations and targeted delivery to the site of action appear possible, and most importantly, recognition of encapsulated allergen by the immune system, especially by IgE antibodies, is prevented. AIT with nanoparticles (NPs) may offer a safer and potentially more efficient way of treatment for allergic diseases. In this review, we summarize the use of biodegradable NPs consisting of synthetic or natural polymers, liposomes, and virus‐like particles as well as nonbiodegradable NPs like dendrimers, and carbon‐ or metal‐based NPs for AIT. More or less successful applications of these NPs in prophylactic as well as therapeutic vaccination approaches in rodents or other animals as well as first human clinical trials are discussed in detail.

show abstract

“…This surface modification reduces clearance of nanoparticles by the cells of the RES and apparently prolongs the duration of nanoparticles remaining in circulation. 5,[7][8][9] Lipid-PEGs, especially DSPE-PEG2000, have been extensively used to prepare stealth liposomes. 7,8,10,11 Although the PEG-coating brings prolonged circulation time and enhanced accumulation at the tumor site via the EPR effect, the highly hydrophilic surface is unfavorable for the internalization of liposomes by tumor cells.…”

Section: Introductionmentioning

confidence: 99%

“…5,[7][8][9] Lipid-PEGs, especially DSPE-PEG2000, have been extensively used to prepare stealth liposomes. 7,8,10,11 Although the PEG-coating brings prolonged circulation time and enhanced accumulation at the tumor site via the EPR effect, the highly hydrophilic surface is unfavorable for the internalization of liposomes by tumor cells. 3,6,10 Thus, the anticancer efficiency of stealth liposomes containing DSPE-PEG2000 both in vitro and in vivo is far from what has been expected.…”

Section: Introductionmentioning

confidence: 99%

Poly(ethylene glycol)-block-poly(ε-caprolactone)– and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery

Li¹,

He²,

Su³

et al. 2015

IJN

View full text Add to dashboard Cite

Background Effective anticancer drug delivery to the tumor site without rapid body clearance is a prerequisite for successful chemotherapy. 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine-N-(methoxy[polyethyleneglycol]-2000) (DSPE-PEG2000) has been widely used in the preparation of stealth liposomes. Although PEG chains can efficiently preserve liposomes from rapid clearance by the reticuloendothelial system (RES), its application has been hindered by poor cellular uptake and unsatisfactory therapeutic effect. Methods To address the dilemma, we presented a facile approach to fabricate novel stealth nanoparticles generated by poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG- b -PCL), soybean phosphatidylcholine (SPC), and cholesterol, namely LPPs (L represented lipid and PP represented PEG- b -PCL), for the delivery of anticancer drug paclitaxel (PTX). LPPs were prepared using the thin film hydration method. Two PEG- b -PCL polymers with different molecular weights (MW; PEG2000-b-PCL2000, MW: 4,000 Da and PEG5000-b-PCL5000, MW: 10,000 Da) were used to fabricate stealth nanoparticles. Conventional PEGylated liposome (LDP2000, L represented lipid and DP2000 represented DSPE-PEG2000) composed of SPC, cholesterol, and DSPE-PEG2000 was used as the control. The physical properties, cellular uptake, endocytosis pathway, cytotoxicity, pharmacokinetics, tumor accumulation, and anticancer efficacy of free PTX, PTX-loaded LPPs, and LDP2000 were systemically investigated after injection into 4T1 breast tumor–bearing mice. Results LPPs were vesicles around 100 nm in size with negative zeta potential. With enhanced stability, LPPs achieved sustainable release of cancer therapeutics. The cellular uptake level was closely related to the PEG chain length of PEG- b -PCL; a shorter PEG chain resulted in higher cellular uptake. Moreover, the cellular internalization of LPP2000 modified by PEG2000- b -PCL2000 on 4T1 cells was 2.1-fold higher than LDP2000 due to the improved stability of LPP2000. The cytotoxicity of PTX-loaded LPP2000 was also higher than that of LDP2000 and LPP5000 as observed using a WST-8 assay, while blank LPPs showed negligible toxicity. Consistent with the results of the in vitro study, in vivo experiments showed that LPPs allowed significantly improved bioavailability and prolonged T 1/2β as compared to free PTX injection. More importantly, LPPs mainly accumulated at the tumor site, probably due to the enhanced permeation and retention effect (EPR effect). As a nanomedicine, LPP2000 (tumor inhibition rate of 75.1%) significantly enhanced the therapeutic effect of PTX in 4T1 breast tumor–bearing mice by inhibiting tumor growth compared to LDP2000 and LPP5000 (tumor inhibition rates of 56.3% and 49.5%, respectively). Conclusion Modification of li...

show abstract

Suppression of immune response by antigen-modified liposomes encapsulating model agents: A novel strategy for the treatment of allergy

Cited by 20 publications

References 22 publications

Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment

Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment

Recent advances in the use of nanoparticles for allergen‐specific immunotherapy

Poly(ethylene glycol)-block-poly(ε-caprolactone)– and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery

Contact Info

Product

Resources

About

Suppression of immune response by antigen-modified liposomes encapsulating model agents: A novel strategy for the treatment of allergy

Cited by 20 publications

References 22 publications

Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment

Bauhinia purprea agglutinin‐modified liposomes for human prostate cancer treatment

Recent advances in the use of nanoparticles for allergen‐specific immunotherapy

Poly(ethylene glycol)-block-poly(&epsilon;-caprolactone)&ndash; and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery

Contact Info

Product

Resources

About

Poly(ethylene glycol)-block-poly(ε-caprolactone)– and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery